Commonwealth Equity Services, LLC Lineage Cell Therapeutics, Inc. Transaction History
Commonwealth Equity Services, LLC
- $68.4 Billion
- Q4 2024
A detailed history of Commonwealth Equity Services, LLC transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Commonwealth Equity Services, LLC holds 58,708 shares of LCTX stock, worth $39,921. This represents 0.0% of its overall portfolio holdings.
Number of Shares
58,708
Previous 48,261
21.65%
Holding current value
$39,921
Previous $44,000
31.82%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding LCTX
# of Institutions
134Shares Held
106MCall Options Held
22.1KPut Options Held
0-
Broadwood Capital Inc New York, NY41.7MShares$28.3 Million1.65% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$6.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.63MShares$5.87 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY7.24MShares$4.92 Million0.12% of portfolio
-
Defender Capital, Llc.5.96MShares$4.06 Million1.17% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $115M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...